Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Buyers Club Aims For Lower-Cost Cystic Fibrosis Drugs

Executive Summary

A buyers club in the UK is planning to import generic versions of Vertex’s cystic fibrosis drugs that are not available on the NHS.  Some commentators think such clubs may become more common.

You may also be interested in...



More Drug Price Disclosure In Store As WHO Delegates Pass Landmark Resolution

Many see the World Health Assembly resolution on drug pricing transparency as a game changer and welcome the fact that it will shine light on an area that critics says is far too opaque. Some are unhappy that the final version is not as strong as the original draft, but industry will be relieved the WHA ultimately did not adopt a requirement for mandatory disclosure of R&D costs. 

NHS England Offers ‘Improved’ Orkambi Deal, But Vertex Lukewarm

The NHS in England says it has made a “revised and improved” offer to Vertex to make Orkambi available, but the company is not impressed and says its attitude to the negotiations has been mischaracterized.

Industry Calls For Canadian Pricing Guideline Consultation To Be Suspended

IMC, the R&D-based pharmaceutical industry association in Canada, says the guideline will “exacerbate an already unpredictable regulatory environment.”

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel